Tratamiento de conversión en población seleccionada
PLANET study
RAS
analysis
ORR (WT
RAS
)
•
Abad A, et al. Ann Oncol 2014;25(Suppl 4):iv189 (poster
551P).
•
†
Not confirmed, patients resected before response
confirmation.
Panitumumab
+ FOLFOX4
(n = 27)
Panitumumab
+ FOLFIRI
(n = 26)
ORR
†
, n (%)
21 (77.8)
19 (73.1)
(95% CI)
(62.1−93.5)
(56.0−90.1)
52.8%
(39.4−66.3)
n = 28
39.6%
(26.4−52.8)
n = 21
0%
20%
40%
60%
80%
100%
Surgical resection
Resection rate (R0 + R1)
N = 53
Percentage of patients
(95% CI)
0
20
40
60
80
100
R0 = 32.1%
R1 = 7.5%
